DEF 14A: Cassava Sciences Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Cassava Sciences will hold its 2024 Annual Meeting of Stockholders virtually on May 9, 2024, to vote on director elections, auditor ratification, and executive compensation.

Summary

• Cassava Sciences, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 9, 2024, at 10:00 a.m. Central Time.
• Stockholders of record as of March 19, 2024, are entitled to vote.
• The meeting will address the re-election of three Class III Directors (Remi Barbier, Sanford R. Robertson, and Patrick J. Scannon), ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024, and a non-binding advisory vote on the 2023 executive compensation.
• The Board of Directors recommends voting FOR all proposals.
• Stockholders can vote via internet, phone, or mail, or virtually attend the Annual Meeting and vote electronically.
• The proxy statement and annual report are available online.
• As of the record date, there were 43,245,758 shares of Common Stock outstanding and entitled to vote.
• The company's principal executive offices are located in Austin, Texas, and the telephone number is (512) 501-2444.
• The proxy statement and related materials were first mailed on or about April 3, 2024.
• The company may reimburse persons representing beneficial owners of Common Stock for their costs of forwarding solicitation materials to such beneficial owners.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining meeting details and proposals. While it expresses appreciation for stockholder support, it lacks strong positive or negative sentiment. The inclusion of forward-looking statements and risk factors tempers any potential optimism.

Positives

• The company is embracing virtual technology to provide expanded access, improved communication and cost savings for its stockholders.
• The Board of Directors has determined that all members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are independent and satisfy the relevant SEC and Nasdaq independence requirements for such committees.
• The company has adopted an executive compensation clawback policy as required pursuant to the listing standards of Nasdaq, Section 10D of the Exchange Act and Rule 10D-1 under the Exchange Act (the Dodd-Frank Clawback Policy).

Negatives

• The company incurred legal fees of $4,489,000 with Orrick, Herrington & Sutcliffe LLP in 2023, where director Michael J. O'Donnell is a partner, although the company states that the services were provided in the ordinary course of business and on substantially the same terms as other comparable transactions with third parties.
• The company reported a net loss of $97,217,000 in 2023.

Risks

• The document contains forward-looking statements that involve risks and uncertainties, and actual results may differ materially from those discussed.
• The company is subject to risks described in Item 1A. Risk Factors section of the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
• The company cannot assure that it will realize the results or developments it expects or anticipates.

Future Outlook

The proxy statement contains forward-looking statements regarding future results of operations, financial position, clinical trials, business strategy, and anticipated events or trends, but the company undertakes no obligation to update these statements.

Management Comments

• Remi Barbier, Chairman of the Board, President and Chief Executive Officer, expressed appreciation for stockholders' ongoing support of the company's research and development programs.
• The company values and encourages broad investor participation in the Annual Meeting.

Industry Context

The document provides information relevant to investors in the biotechnology industry, particularly those interested in companies developing treatments for Alzheimer's disease.

Comparison to Industry Standards

• The company established a peer group of 14 publicly traded pre-commercial biotechnology companies with market capitalizations ranging from approximately $500 million to $2 billion for compensation analysis.
• The peer group includes companies such as Alector, Inc., Avidity Biosciences, Inc., Prothena Corporation plc, and Denali Therapeutics Inc.
• The company's market capitalization was approximately at the 55th percentile of this peer group of companies at the time it was established.
• Based on Pearl Meyer's analysis of this peer group (i) annual cash and initial equity compensation (assuming service on two standing Board committees) per non-employee director approximates the 70th percentile of the peer group for total initial year compensation per average director and (ii) annual cash and annual equity compensation (assuming service on two standing Board committees) per non-employee director approximates the 55th percentile of the peer group for total annual compensation per average director.

Corporate Governance

Related Party Transactions

• During 2023, Orrick, Herrington & Sutcliffe LLP provided legal services to the Company, and Mr. O'Donnell, a director of the Company, is a member of Orrick. For the fiscal year 2023, the Company paid Orrick a total of $4,489,000 for legal services.
• Our Senior Vice President, Neuroscience is the spouse of our President and Chief Executive Officer. Our Senior Vice President, Neuroscience has a base annual salary as of January 1, 2024 of $490,000.

Stakeholder Impact

• The proposals to be voted on at the Annual Meeting will impact shareholders' rights and the company's governance structure.
• Executive compensation decisions impact executive officers and potentially other employees.
• The selection of an independent auditor affects the reliability of the company's financial statements.

Next Steps

• Stockholders are urged to vote their shares via internet, phone, or mail.
• Stockholders can attend the virtual Annual Meeting on May 9, 2024, and vote electronically.
• The company plans to hold another say-on-pay advisory vote in 2025.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Cassava Sciences, Voting, Auditor, Governance, Clinical Trials